# Attempt 004 — Claim-Backing Audit: medical/PATIENT_ZERO_TIMELINE.md + CVB_VACCINE_STRATEGY.md

**Date**: 2026-04-15
**Phase**: Audit (cross-cutting, AUDIT_LOG.md queue)
**Scope**: PATIENT_ZERO_TIMELINE.md (330 lines, sampled L240–320
where R26 WHM reference lives) + CVB_VACCINE_STRATEGY.md (204
lines, sampled L1–80).
**Standard**: math/ns_blowup/attempts/attempt_849_frobenius_ratio_gap.md
**Prior**: R26 first flagged Fire 12; consolidated sweep Fire 25.

## Executive verdict

**PATIENT_ZERO_TIMELINE**: week-by-week implementation plan with 7
explicit decision gates. Contains the R26 WHM NF-κB-lockdown claim
at L251 (matches Fire 25 inventory location #5). No new issues
beyond the pending WHM sweep.

**CVB_VACCINE_STRATEGY**: sequence-conservation table + **novel
BiComponent vaccine design** (humoral VLP-ΔVP4 + cellular 3A CTL
against intracellular persistence). First candidate explicitly
targeting the chronic phase.

**🔴 RED count**: 1 (R26 re-flag, already inventoried)
**🟡 YELLOW count**: 5
**🟢 GREEN count**: 9

## RED findings

### R34 — PATIENT_ZERO_TIMELINE.md L251 (R26 WHM re-flag)

Identical to R22/R24/R29 pattern: "Intermittent hypoxia →
epinephrine spike → β-arrestin-2 → NF-κB lockdown". This is the
5th 🔴 location inventoried in `WHM_NFkB_CROSS_SUBDIR_FIX.md`
(Fire 25). Not a new finding — confirmation that Fire 25's sweep
inventory is correct. Fix applies here when the operator approves.

## YELLOW findings

| # | File / line | Claim | Source gap |
|---|-------------|-------|------------|
| Y199 | CVB_VACCINE L38 | "3A membrane anchor 97.4% conserved" across CVB1-6 | Thread the numerics file (pattern 013 / attempt 072) |
| Y200 | CVB_VACCINE L35-39 | VP1 ~40%, VP2 ~55%, VP3 ~50% conservation | Per-serotype variation needed — current values are rounded |
| Y201 | CVB_VACCINE L71-80 | Soppela VLP-ΔVP4 "Preclinical" + "3-5 years if funded" | Status + timeline are estimates; clinical-trial registry check advisable |
| Y202 | CVB_VACCINE L42-52 | BiComponent design with 3A CTL arm | Proposed design — **label as not-yet-published** to distinguish from existing literature |
| Y203 | PATIENT_ZERO_TIMELINE L289 | "CVB serology (if available — tracking antibody response)" | Specialty-lab access caveat; not routine in most clinical settings |

## GREEN findings

- **G210** PATIENT_ZERO_TIMELINE L305-316 — **7 Decision Points**:
  Week 1 C-peptide → ambition level; Week 1 cardiac/hepatic → drug
  selection; Week 4 foundation tolerance → antiviral; Week 8
  fluoxetine tolerance → FMD; Week 13 first C-peptide → protocol
  check; Month 6 midpoint → continue/modify/escalate; Month 12
  final → success/partial/failure. Each gate has specific data
  input.
- **G211** PATIENT_ZERO_TIMELINE L276-303 — Quarterly monitoring
  cadence with specific labs per quarter + cardiac markers at
  months 6 and 12 (safety monitoring).
- **G212** PATIENT_ZERO_TIMELINE L302-303 — **"Publish findings
  regardless of outcome (both positive and negative results
  matter)"** — explicit commitment to publishing negative results.
  Matches sigma v2 "formalize dead ends" principle.
- **G213** CVB_VACCINE L29-52 — **Sequence Conservation Table**
  per-protein conservation + surface-exposed status + vaccine use
  classification. 5' cloverleaf nt 1-10 at 100% conservation
  supports TD mutant diagnostic use.
- **G214** CVB_VACCINE L42-52 — **3A Insight**: NO current vaccine
  candidate targets the chronic intracellular phase (all focus on
  extracellular neutralization). Correct gap identification.
- **G215** CVB_VACCINE L53-64 — **BiComponent vaccine proposal**:
  VLP-ΔVP4 humoral arm + 3A CTL cellular arm with explicit division
  of labor (WT clearance vs TD-infected cell killing). Novel,
  testable, mechanism-grounded.
- **G216** CVB_VACCINE L66 — "Priority recommendation: add 3A
  peptide library to mRNA vaccine design" — actionable for vaccine-
  design partners. Specific deliverable.
- **G217** CVB_VACCINE L73-78 — Soppela VLP-ΔVP4 detailed with
  rationale for VP4 deletion ("prevents ADE — sub-neutralizing
  antibodies help virus enter cells"). ADE risk explicitly
  acknowledged as the safety concern that killed prior CVB vaccines.
- **G218** PATIENT_ZERO_TIMELINE L260-273 — Week 13 First Follow-up
  with THREE possible outcomes (improved/stable/declined) each
  triggering a specific action tree. Pre-committed branch logic.

## Recommended fixes (ordered)

1. **[P0]** Apply Fire 25 WHM sweep Option A to PATIENT_ZERO_TIMELINE
   L251 along with the other 4 🔴 locations.
2. **[P1]** CVB_VACCINE Y199: thread pattern 013 / attempt 072 as
   source for 97.4% 3A conservation number.
3. **[P2]** CVB_VACCINE Y202: add "Proposed, not yet published"
   label to BiComponent design section to distinguish from
   existing vaccine candidates.
4. **[P2]** PATIENT_ZERO_TIMELINE Y203: note availability caveats
   for non-routine tests (CVB serology, cfRNA biomarker panel).

## Non-audit observations

- **Campaign documentation set now 8 master docs audited**:
  CLINICAL_BRIEF + EVIDENCE_GRADES + DRUG_SAFETY_MATRIX + FAILURE_
  MODES + CONVERGENCE + MEDICAL_PROBLEMS + PATIENT_ZERO_TIMELINE +
  CVB_VACCINE_STRATEGY. Plus the meta audits (WHM sweep, K-framework,
  α/β/γ framework).
- **CVB_VACCINE_STRATEGY is distinctive** — the BiComponent design
  is a concrete research-direction proposal, not just synthesis of
  existing candidates. If the 3A-CTL arm argument holds, this is a
  publishable idea for vaccine-design literature.
- **7 medical/ top-level docs remain**: PATIENT_ZERO_SCREENING (141),
  PRE_EXPOSURE_PREVENTION (117), FOR_YOUR_DOCTOR (128), GEO_DATASET_
  CATALOG (178), PREVENTION_STRATEGY (235), DISEASE_DATA_SUMMARY (404),
  THEWALL.md (123).

## Tag

004 (medical/ top-level). Audited PATIENT_ZERO_TIMELINE.md +
CVB_VACCINE_STRATEGY.md. 1 🔴 R34 (re-flag of R26 WHM at L251 —
already in Fire 25 sweep inventory, no new action). 5 🟡 (3A 97.4%
conservation numerics-file, per-serotype conservation variation,
Soppela timeline, BiComponent-design label, specialty-lab caveats).
**9 🟢**: PATIENT_ZERO_TIMELINE 7-decision-gate structure,
quarterly monitoring cadence, **explicit commitment to publishing
negative results**; CVB_VACCINE sequence-conservation table,
3A-insight gap identification, **novel BiComponent vaccine design
proposal** (first candidate explicitly targeting chronic phase),
actionable 3A-peptide-library priority recommendation, Soppela
VP4-deletion rationale for ADE prevention, Week-13 pre-committed
branch logic. Campaign documentation set now 8 master docs
audited. 7 medical/ top-level docs remain (~1400 lines). Next
fire: continue medical/ / biology attempts / WHM sweep (pending).
